According to ARS, the FDA regulators decided at the time that more data was needed to evaluate the safety of repeated doses of the nasal spray before it could be approved. "Neffy is epinephrine ...

On Friday, the FDA announced the approval of neffy, an epinephrine nasal spray by ARS Pharmaceuticals ... associate director of the Division of Pulmonology, Allergy and Critical Care in the ...

Emergency crews were called to the scene after a semi crashed into a building in West Chicago on Wednesday afternoon. A federal judge is expected to rule on a request to stop President Trump's ...

allergy and critical care at the FDA's Center for Drug Evaluation and Research (CDER). "The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis.

"FDA approves Neurelis’ nasal spray for seizures" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in ...

Residents living near 19th and Market Street in the lower downtown area say they have had enough with the crime happening in their community.

The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...

A report from the Department of Homeland Security about a man whose case has received national attention after he was deported from Maryland to El Salvador alleged that he was pulled over by the ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression. No More Pricking: US FDA Approves ...

Nasal spray offers an alternative for patients who ... “The goal for developing Nasdepi is to simplify protecting severe allergy patients from the potential of anaphylaxis,” Scott Lyman ...